The global ophthalmic drugs market value is expected to reach around US$ 40 billion by 2026 growing at noteworthy CAGR of 4.2 % throughout the forecast period 2019 to 2026.
The report provides analysis of global Ophthalmic Drugs market for the period 2015-2026, wherein 2019 to 2026 is the forecast period and 2018 is considered as the base year.
The treatment of glaucoma, cataracts, retinopathy, and other epithelial disordere is widely used in ophthalmic drugs. The launch of new approaches to the delivery of ocular pharmaceuticals has led manufacturers to develop innovative therapeutic approaches to treat ophthalmic disorders. 11 million people in the U.S. have age-related macular degeneration (AMD), whereas approximately 10% of them suffer wet AMD, according to the American Academy of Ophthalmology. Such trends in eye diseases worldwide contribute to market growth.
The main factors attributed to the growth of the market of ophthalmic medicines include increased eye incidence and prevalence, increased R&D activities in the development of new pharmaceuticals and a growing focus on the development of combination therapies. Global demand for ophthalmic drugs is rising as the prevalence of eye diseases increases. The eye condition has been identified in many developed and developing countries as possible threats to people's sight. Diabetic retinopathy has been added to the priority list due to the increased prevalence of diabetes in several countries. Because of difficulties with the early diagnosis of glaucoma and frequent need for lifetime treatment, it is known over the centuries that this disease remains on the public health agenda.
WHO estimates in 2018 that some 1.3 billion people had a vision impairment, 188,5 million were poorly visible, 217 million were moderately to severe, and 36 million were blind. The WHO estimates that there were 36 million people. Globally, uncorrected refractive errors and cataracts are the leading causes of vision impairment and the majority of visually impaired people are over 50 years of age. According to the WHO, chronic eye disease is the number one cause of vision loss and refractive errors and uncorrected cataracts represent the two main causes. The first is the leading cause in low-and middle-income countries. Over 80 percent of visual impairments are curable or preventable, meaning these medicines are necessary for disease management. Therefore, the increased incidence of eye disorders is projected to have a major impact on market growth.
Drug Class Outlook
The main classes of drugs include antiallergies, anti-bluetongueagents, anti-inflammatoryand anti-VEGF agents. Due to its wide application in Age-related Macular Degeneration (AMD), diabetic retinopathy and retinal vein occlusion, anti-VEGF agents led the market in 2018 with a margin share of over 30 percent. The anti-VEGF segment should also be seen in the forecast period as fast as possible in CAGR. This is because differthe treatments with new mechanisms, in particular for the treatment of AMD such as Macugen (pegaptanib), Lucentis (ranibizumab), and Avastin (bevacizumab), have been introduced. Further segmented anti-inflammatory into steroidal and non-steroidal medicines the biggest segment was in non-steroid medicines in 2018, with the most rapid growth in the forecast year estimated in the steroid drug segment.
The dry eye, glaucoma, retinal disorders, inflammation / infection, allergy, and uveitiis are the segments of the market, based on disease. In 2018, the segment of retinal diseases led the market. Retinal disorders with CAGRs of 7.6% from 2019 to 2026 due to the increasing prevalence of diabetes are predicted to be the fastest growing segment. The potential risk of blindness in a diabetes person is 2.4 times higher than in diabetes-free people, says a study by the VISION Loss Expert Group of the Global Burden of Disease Study. Because of the presence of many pipeline drugs, glaucoma is the second largest segment. For example, OTX - TP is undergoing phase three tests by Ocular Therapeutix, Inc. to analyze the decrease in the intraocular pressure associated with eye blood pressure and glucose.
Dosage Form Stance
The market is divided into gels, capsules and tablets, eyes, eye drops and ointments according to dosage form. Eye drops were leading the market in 2018, with the fastest growth likely since they are economical compared to other dosages. The growth of the segment is further encouraged by the growth of innovative treatments in the form of eye drops. In 2017, for example, the first low dose of brimonidine OTC eye drop for the treatment of redness of the eye was approved for LUMIFY in the FDA system by Bausch&Lomb Inc.
The market is divided into OTC and prescription medicines on the basis of product type. The largest segment of prescription drugs in 2018 was OTC-effective and used in treatments such as cataracts and inflammations in the post-surgical procedure. Due to the easy accessibility of these therapy products, OTC type is projected to be the fastest growing segment over the prediction time. They are also available in various dosage forms, including ointment, ointment, eye drops, gels and capsules, designed to help boost demand for the product in this segment.
Due to the presence of major companies and well-established health infrastructures, North America led the market in 2018. Due to increasing geriatric populations and the prevalence of eye-related distress, the region is projected to maintain dominance in the forecast years. In 2017, more than 3 million Americans had glaucoma, according to an article published in the Bright Focus Foundation. The maximum growth in Asia-Pacific for 2019 to 2026 is expected because of increased disposable incomes and increased early diagnostic awareness. In addition, new technologies have improved healthcare facilities on developing markets, including India and China, thereby promoting expansion in the market.
By Drug Class Outlook
By Disease Outlook
By Dosage Form
By Product Type
The market research study on “Ophthalmic Drugs Market (By Drug Class Outlook: Antiallergy, Anti-Vascular Endothelial Growth Factor (Anti-VEGF) Agents, Anti-inflammatory [Nonsteroidal Drugs, Steroidal Drugs], Antiglaucoma, Others; By Disease Outlook: Dry Eye [Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments], Allergies [Gels, Eye Solutions, Capsules & Tablets, Eye drops, Ointments], Glaucoma [Gels, Eye Solutions, Capsules & Tablets, Eye drops, Ointments], Inflammation/Infection [Gels, Eye Solutions, Capsules & Tablets, Eye drops, Ointments], Retinal Disorders [Gels, Eye Solutions, Capsules & Tablets, Eye drops, Ointments], Uveitis [Gels, Eye Solutions, Capsules & Tablets, Eye drops, Ointments], Others; By Dosage Form: Gels, Eye Solutions, Capsules & Tablets, Eye Drops, Ointments; By Product Type: Prescription Drugs, OTC Drugs) - Global Industry Analysis, Market Size, Opportunities and Forecast, 2019 - 2026” offers detailed insights on global Ophthalmic Drugs market segments with market dynamics and their impact. The report provides insights on global Ophthalmic Drugs market by Product, Dosage Form, Disease, Drug Class and major geographic regions. The report also covers basic technology development policies.
The report offers an overview of the market and statistical diagrams to support the expected figures. Our analysts predict the market scope and future prospects in an insightful way. The Acumen Research and Consulting report contains a comprehensive analysis of the global market in Ophthalmic Drugs segmented by molecular type, test type and region. The report outlines numerous growth strategies implemented by companies as well as the latest market trends. The market share and current position of all leading players are discussed in detail. It analyzes players ' new revenue sources and highlights the different strategies.
Key Players & Strategies
The Ophthalmic Drugs market is consolidated with large number of manufacturers. The company profiling of key players in the market includes major business strategies, company overview and revenues. The key players of the market are ALLERGAN PLC ; Pfizer, Inc. ; Santen Pharmaceutical Co., Ltd. ; Johnson & Jean - Services, Inc. ; Merck Sharp & Dohme Corp. ; and Genentech, Inc. AG ; Bausch & Lomb, Inc. ; Regeneron Pharmaceutical, Inc., among others.
Santen Pharmaceuticals has been approved for the treatment of Severe Vernal Keratoconjunctivitis in pediatric patients by the Committee of Human Medicinal Products (CHMP) in 2017 for the marketing of its product, cyclosporine, in Europe. In the same year Genentech, Inc. was approved for the treatment of diabetic retinopathy by the FDA for its product, Lucentis, to improve its product portfolio.
In addition to improving their profitability and gaining a competitive edge on other players, the key players on the Ophthalmic Drugs market employ new ideas and concepts, improve production processes and improve the existing set of products. The key players therefore have taken product development as their key development strategy to be consistent with end users ' demands.